- Medicaid authorities in Pennsylvania and Colorado limit access to Gilead Sciences' (GILD) Sovaldi to only the sickest hepatitis C patients citing the exorbitant cost of $84,000 for a 12-week regimen.
- The $1,000/day pill is too expensive to offer many patients who are likely infected with the disease despite the fact that it works better and has fewer side effects than alternative therapies.
- Hepatitis C sufferers are more likely to be minorities with annual incomes below $23,000.
- The recently-FDA-approved Sovaldi generated $139M in sales in December, its first month commercially available.
From other sites
at 4-traders.com (Mar 24, 2015)
at MarketRealist.com (Mar 24, 2015)
at Nasdaq.com (Mar 17, 2015)
at Zacks.com (Mar 6, 2015)
at Benzinga.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs